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Abstract 
Hypertension is a key risk factor for cardiovascular disease and new treatments are needed. 
Uric acid reduction lowers blood pressure in adolescents suggesting a direct 
pathophysiological role in development of hypertension. Whether the same relationship is 
present in older adults is unknown. We explored change in blood pressure after allopurinol 
initiation using data from the UK Clinical Practice Research Datalink. 
Data were extracted for patients with hypertension aged >65-years who were prescribed 
allopurinol with pre and during treatment blood pressure readings. Data from comparable 
controls were extracted. The change in blood pressure in patients with stable blood pressure 
medication was the primary outcome and was compared between groups. Regression analysis 
was used to adjust for potential confounding factors and a propensity-matched sample was 
generated. 
365 patients who received allopurinol and 6678 controls were included. Blood pressure fell in 
the allopurinol group compared to controls (between group difference in systolic and 
diastolic blood pressure 2.1 mmHg (95%CI -0.6 to 4.8) and 1.7 mmHg (95%CI 0.4 to 3.1), 
respectively). Allopurinol use was independently associated with a fall in both systolic and 
diastolic blood pressure on regression analysis (p<0.001). Results were consistent in the 
propensity-matched sample. There was a trend toward greater fall in blood pressure in the 
high dose allopurinol group but change in blood pressure was not related to baseline uric acid 
level. 
Allopurinol use is associated with a small fall in blood pressure in adults. Further studies of 
the effect of high dose allopurinol in adults with hypertension are needed.  
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INTRODUCTION 
Hyperuricaemia is associated with incident hypertension [1] and preclinical studies support a 
role for hyperuricaemia in the development of hypertension. Hyperuricaemia has been shown 
to raise blood pressure (BP) in normotensive rats and this rise is attenuated by urate lowering 
drugs [2]. Further, sustained hyperuricaemia has been shown to induce a primary renal 
arteriolopathy and a salt sensitive rise in BP in experimental models [3].  
Recently, randomised placebo controlled and blinded clinical trials have shown that urate 
lowering drugs reduce BP in hyperuricaemic, hypertensive adolescents and in obese 
adolescents with pre-hypertension [4,5]. In one study, both allopurinol (a xanthine oxidase 
inhibitor which reduces formation of uric acid) and probenecid (a uricosuric drug) were 
studied [5]. For similar reductions in uric acid, both agents were associated with significant 
reduction in systolic BP, suggesting the effect is mediated by uric acid reduction per se. 
Whether serum uric acid has a direct pathophysiological role in the sequelae of hypertension 
in older adults is less clear. A recent analysis of 6984 patients undergoing treatment for 
hypertension showed no relationship between baseline serum uric acid level and long term 
BP change, although it did show an association between high uric acid level and decline in 
renal function [6]. Equally, it is less clear whether drugs that lower uric acid lower BP in 
adults with hypertension. A meta-analysis of the effect of allopurinol on BP, combining data 
from 10 clinical studies with 738 participants, found a small reduction in BP in allopurinol 
treated patients (3.3mmHg (95% CI: -1.4 to -5.3mmHg) for systolic BP [7].  
We hypothesised that, similar to in adolescents, the initiation of allopurinol would be 
associated with a fall in BP in older adults with hypertension and that higher doses would 
have a greater effect. We extracted data from the UK Clinical Practice Research Datalink 
(CPRD) to test this hypothesis.  
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MATERIALS AND METHODS 
The CPRD (formally GPRD) is the world’s largest computerized database of anonymized 
longitudinal clinical records from primary care’ [8]. It contains data on demographic 
characteristics, diagnoses, prescriptions, referrals to secondary care and medical history [9]. 
Information is collected from over 500 practices giving details of over 3.4 million patients 
and the information contained within the database has been shown to be accurate and 
representative of the UK population [10,11].  
Approval was granted by the Independent Scientific Advisory Committee of the CPRD for 
access to the database for this study. Ethical approval for all purely observational studies 
using CPRD data has been granted by the National Research Ethics Service.  
Study Cohort 
Data on 44,406 patients were obtained from the CPRD. The cohort included all patients with 
hypertension aged 65 years or older who were registered with the CPRD on 1 January 1996 
with two or more years of up to standard follow-up data prior to this date. Hypertension was 
defined as a documented record of hypertension with onset within 10 years prior to cohort 
entry or at least two BP readings of more than 160/90mmHg within the same period. Age was 
derived from date of birth records in the CPRD. It was decided to include patients aged 65 
years or more as they are exempt from prescription charges in the UK which reduces the risk 
of income-based confounding and our aim was to explore the effect of allopurinol in older 
adults with established hypertension.  
Patients with a diagnosis of renal impairment, chronic obstructive pulmonary disease, 
asthma, rheumatoid arthritis or migraine were excluded as these could confound 
antihypertensive and other medication choices. 
From this initial cohort of 44,406 patients, two groups were extracted for inclusion in this 
study (an allopurinol group and a control group). Patients were included in the allopurinol 
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group if they were prescribed allopurinol and had a BP measured before and during 
allopurinol treatment.  Control patients had at least two BP measures recorded at least 30 
days apart. A pre-allopurinol treatment serum uric acid level was extracted for allopurinol 
treated patients. 
Allopurinol exposure 
Allopurinol is identified by the British Formulary Classification as class 10.1.4. Allopurinol 
use was defined as > 3 prescriptions of allopurinol after 1st January 1996. The number of 
prescriptions, the date of the prescriptions and the dosages of the prescriptions were 
extracted.  
The dosages were used to calculate the number of mg of allopurinol received and this was 
used to classify participants into high (≥300 mg daily) and low dose (<300 mg daily) 
allopurinol groups. 
Blood pressure readings 
For both groups, two BP readings were extracted; a baseline measurement and a subsequent 
measurement. For the allopurinol group the baseline (pre-treatment) BP was defined as the 
BP reading on the day of or closest to and within one calendar year of the first allopurinol 
prescription date. The second measure was at least 30 days after starting (but still during) the 
allopurinol treatment. The difference between these measurements was calculated.  
For the patients not receiving allopurinol the baseline BP was the first measurement obtained 
after 1 January 1996 and the second BP reading was taken at least 30 days thereafter. The 
difference between these BP measurements was calculated. 
Antihypertensive drug exposure 
Data regarding patient’s antihypertensive medication use was also obtained. The dates and 
number of prescriptions were obtained for drugs belonging to the following drug classes: 
angiotensin-converting enzyme inhibitors (BNF class 2.5.5.1), angiotensin receptor blockers 
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(BNF class 2.5.5.2), calcium channel blockers (BNF class 2.6.2), any diuretic class (BNF 
class 2.2), beta blockers (BNF class 2.4) and alpha blockers (BNF class 2.5.4).  
Based on this study subjects were organised into two groups; those receiving ‘new 
antihypertensive treatment’ (if their first prescription above was received within 30 days 
before the (pre-allopurinol) baseline BP or between baseline and the on-allopurinol BP 
reading) and those with ‘no antihypertensive treatment or continued unchanged 
antihypertensive treatment’ (if the patients were not prescribed any antihypertensive 
treatment at all or continued on the same treatment as when the baseline BP was measured).  
Outcomes of interest 
The primary outcome was the change in SBP between the baseline and subsequent BP 
readings. The secondary outcome was the change in DBP between baseline and subsequent 
BP readings.  Our primary analysis included patients in the no or continued unchanged 
antihypertensive group. 
Statistical analysis 
A p value of <0.05 was used to define a statistically significant difference for all analyses. 
The change in SBP and DBP was compared between the allopurinol and control group using 
a 2 sample t test (data were normally distributed). One way analysis of variance was used to 
compare the change in BP in the high dose and low dose allopurinol patients. A 2 sample t-
test was then used to compare those with low dose and high dose allopurinol. 
Regression analysis was used to determine if allopurinol was independently associated with 
the change in BP. Variables that were related to either the change in BP or the treatment 
group (allopurinol vs. control) were identified by either correlation analysis for two 
continuous variables or chi squared analysis. 
Analyses were performed separately in the no or continued unchanged antihypertensive 
treatment group (the primary analysis) and then in the new antihypertensive treatment group. 
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In order to further assess the potential for confounding we used nearest neighbour propensity 
matching to refine the control group and repeated the above analyses. Patients were matched 
on the variables that differed between the treatment groups (age, BMI, diabetes, IHD, days 
between BP measurements and for antihypertensive treatment group but not baseline BP as 
this was used to calculate the outcome measures). In the regression models, all matching 
variables, as well as those that differed between the treatment groups or were related to the 
change in BP were included. 
A sensitivity analysis was performed including only patients whose baseline BP was 
measured ≤ 30 days before the initial allopurinol prescription. This was to reduce the effects 
any confounding factors may have during the time between the baseline (pre-treatment) BP 
being obtained and the patient starting allopurinol. 
Finally, we explored the relationship between baseline serum uric acid level and change in 
BP (in the whole group and in males and females separately). We did not have sufficient data 
to calculate a change in uric acid level following allopurinol treatment. 
 
RESULTS 
From the 44,406 patients included in the CPRD data extract 1412 were exposed to 
allopurinol. Of these, 1047 did not have BP data meeting the above criteria. This left 365 
patients included in the allopurinol study group (Figure 1). Of these, 262 (71.9%) received no 
or continued unchanged antihypertensive treatment and 103 (28.1%) started new 
antihypertensive treatment between their BP readings. A total of 133 (36.4%) of patient took 
allopurinol at a dose of 300 mg daily (no patient took a dose higher than this). Pre-treatment 
serum uric levels were available for 202 allopurinol treated patients.  
The median time between the baseline BP measurement and commencing allopurinol was 98 
days [Interquartile range (IQR) 21-271 days]. 308 (84.4%) patients began allopurinol within 
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6 months and 133 (36.4%) within 1 month of their BP measurement (these 133 patients were 
included in the aforementioned sensitivity analysis).  
A total of 6678 patients met the criteria for inclusion in the control group. Baseline 
characteristics for both groups are shown in Table 1. The allopurinol and control groups 
differed significantly for BMI, diabetes, ischaemic heart disease, baseline BP and numbers 
assigned to the two antihypertensive medication groups.    
Blood pressure change during allopurinol treatment 
In those receiving no or continued unchanged antihypertensive treatment SBP fell by 
2.60mmHg [(95%CI: -5.43 to 0.22mmHg) p=0.071] and DBP fell by 2.26mmHg [(95%CI: -
3.81 to -0.71mmHg) p=0.019]. In the new antihypertensive treatment group, SBP decreased 
by 7.82mmHg [(95%CI: -13.4 to -2.26mmHg) p=0.006] and DBP decreased by 4.26mmHg 
[(95%CI: -6.87 to -1.65mmHg) p=0.002].  
Comparison Between Treatment Groups 
Compared to controls, SBP fell by 2.08mmHg [(95%CI: -0.59 to 4.75mmHg) p=0.127] and 
DBP fell by 1.72mmHg [(95%CI: 0.38 to 3.07mmHg) p=0.032] in the allopurinol group for 
those receiving no or continued unchanged antihypertensives. In those receiving new anti-
hypertensives SBP fell to a greater extent in the control group [-4.81mmHg (95%CI: -10.21 
to 0.60mmHg) p=0.081], as did DBP [-2.56mmHg (95%CI: -5.36 to 0.24mmHg) p=0.073] 
(Table 2). However, regression analysis showed allopurinol use to be associated with an 
independent fall in both systolic and diastolic BP in both the “no or continued” and in the 
new anti-hypertensive treatment groups (Table 3a).  Age, smoking, BMI, ischaemic heart 
disease, peripheral vascular disease, cerebrovascular disease, baseline BP, days between BP 
measurements and allopurinol use were included in the regression models.  
BP Change, Allopurinol Dosage and Serum Uric Acid Level 
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One way analysis of variance showed no relationship between the change in SBP and 
receiving no dose, low dose or high dose allopurinol [p=0.312] but did show a significant 
relationship for the change in DBP [p=0.040]. However, the fall in BP in high dose 
allopurinol and low dose allopurinol patients was similar (for SBP high dose: -2.59mmHg 
(95%CI: -7.58 to 2.40mmHg), low dose: -2.61mmHg (95%CI: -6.07 to 0.847mmHg)] and for 
DBP high dose: -2.63mmHg (95%CI: -5.49 to 0.227mmHg), low dose: -2.06mmHg (95%CI: 
-3.91 to -0.22mmHg)).  
There was no relationship between baseline serum uric acid and either change in SBP or DBP 
in either the whole group (r=0.01, p=0.84 and r=-0.04, p=0.60 respectively) or when males 
(r=0.01, p=0.94 and r=-0.00, p=0.97) and females (r=0.02, p=0.86 and r=-0.00, p=0.99) were 
considered separately. 
Propensity Matched Data 
Propensity matching yielded two groups with 313 patients in each; 52 patients from the 
original allopurinol treatment group could not be matched (Table 1). 
In the allopurinol group, SBP fell by 2.09mmHg [(95%CI: -5.14 to 0.95mmHg) p=0.177] and 
DBP fell by 2.0mmHg [(95%CI: -3.69 to -0.30mmHg) p=0.021] in those receiving no or 
continued unchanged antihypertensive treatment. In those receiving new antihypertensive 
treatment SBP fell by 5.67mmHg [(95%CI: -11.7 to 0.36mmHg) p=0.065] and DBP fell by 
3.33mmHg [(95%CI: -6.08 to -0.59) p=0.018] (Table 2).  
Comparison of the propensity matched groups showed SBP to fall by 3.02mmHg (95%CI: -
1.24 to 7.26mmHg, p=0.165) and DBP by 1.71mmHg (95%CI: -0.51 to 3.93mmHg, 
p=0.130) more in the allopurinol group than in the control group for those receiving no or 
continued unchanged antihypertensive treatment (table 3). In patients receiving new 
antihypertensive treatment the fall in SBP and DBP were greatest in the control groups (table 
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3), However, regression analysis again showed allopurinol treatment to be associated with a 
statistically significant and independent drop in BP across all conditions of use (Table 3b).  
One way analysis of variance showed no relationship between the change in systolic or 
diastolic BP and receiving no dose, low dose or high dose allopurinol [SBP change p=0.227, 
DBP change p=0.252]. However, there was a trend towards the fall in both systolic and 
diastolic BP being greater in patients receiving high dose allopurinol (on line supplement). 
Sensitivity Analysis 
The results were compatible with the main study analysis (data not shown).  
 
DISCUSSION 
This study sought to determine whether the initiation of allopurinol is associated with a fall in 
BP in a hypertensive population aged 65 years and older. Allopurinol initiation was 
independently associated with a fall in both systolic and diastolic BP across all conditions of 
use in regression analysis. There was a trend toward a greater fall in BP with high dose 
treatment. The fall in BP was modest (3 mmHg in the propensity matched sample) but was 
independent of adjustment for potential confounding variables and high dose treatment may 
be associated with a higher fall in BP. Although the fall in BP appeared less in patients 
receiving new BP drugs, allopurinol was also associated with a greater fall in BP in this 
group on regression analysis. 
Epidemiological studies have already shown that uric acid level is associated with incident 
hypertension [1] and a role for uric acid in the development of hypertension has been shown 
in clinical trials in adolescents and obese adolescents [4,5]. A meta-analysis of small studies 
that was limited by heterogeneity suggests allopurinol may lower BP in adults [7] and a 
recent clinical trial in patients with stroke found a BP lowering effect [12]. However, this has 
not been demonstrated in trials designed for this purpose, nor in adults with hypertension. 
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The current study suggests, but cannot prove, that allopurinol has a modest effect on BP and 
that higher doses may be particularly effective. 
Uric acid is produced from the metabolism of purines by xanthine oxidase [13,14,15]. Uric 
acid has been shown to cause hypertension and arteriolopathy in rats through activation of the 
renin system and inhibition of nitric oxide synthase [4,5]. In addition, uric acid stimulates 
vascular smooth muscle cell proliferation and acts as a pro-inflammatory mediator. Xanthine 
oxidase activity also produces reactive oxygen species (ROS), namely superoxide, hydrogen 
peroxide and the hydroxyl radical. ROS cause tissue damage and inactivate nitric oxide 
leading to endothelial dysfunction, a precursor for atherosclerosis and vascular injury 
[13,14,15]. Allopurinol inhibits xanthine oxidase activity, thus lowering ROS and improving 
the bioavailability of NO. Treatment with allopurinol has been shown to improve endothelial 
function, measured by forearm blood flow in patients with HF [16] and type 2 diabetes with 
mild hypertension [17]. 
Thus, there are two mechanisms by which allopurinol may lower BP; the reduction in uric 
acid or the reduction in ROS. This dual action makes it an obvious choice for hypertension 
trials. The almost identical reductions in BP from allopurinol and probenicid in obese 
adolescents with prehypertension might suggest that uric acid reduction is responsible for the 
fall in BP [5], confirming that high uric acid is a risk factor for development of hypertension 
in this group.  Whether this is the case in older adults with established hypertension is unclear 
and our study cannot confirm this. We did not see a relationship between baseline serum uric 
acid and change in BP but head to head comparator studies of xanthine oxidase inhibitors and 
uricosuric drugs would be needed to establish the pathophysiological importance of uric acid 
in this group. Were allopurinol to have no effect on BP, it still has other established benefits. 
These benefits are related to xanthine oxidase inhibition and the subsequent decrease in 
oxidative stress and increase in available oxygen and energy. Oxidative stress is associated 
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with the development of left ventricular hypertrophy (LVH). High dose allopurinol has been 
shown to reduce LVH in patients with renal disease [18]. In addition, allopurinol has also 
been shown to improve oxygen consumption in the myocardium [19] and increase the 
delivery of ATP during heart failure [20].  
The dose used in the clinical trials in adolescents was 200mg twice daily [4,5]. In this study, 
patients were prescribed between 100mg and 300mg daily with 58% being prescribed only 
100mg.Previous studies show a steep dose-response relationship for the action of allopurinol 
and suggest higher doses of allopurinol (300 mg twice daily) are needed to exert effects on 
endothelial function and left ventricular hypertrophy [18]. It may be that these doses are 
required for a beneficial BP effect. Allopurinol for the treatment of gout can be given up to 
900mg daily in patients without impaired renal function [21]. Although our study did not 
conclusively show a greater effect of higher doses, we believe the totality of evidence 
supports use of doses of 300 mg daily and above in future studies. The modest fall in BP 
observed could also reflect the older population with established hypertension included in 
this study. The Framingham study showed the association between hypertension and uric acid 
level to weaken as age and duration of hypertension increased [22] and our previous analyses 
support this [6]. 
There are several limitations in this to consider. There is a risk of selection bias in this study 
– only 3.18% of patients from the extracted cohort were prescribed allopurinol treatment. 
Reassuringly, this is in keeping with a primary care study from the General Practice 
Hypertension Study Group which found the prevalence of gout to be 3.1% in patients with 
hypertension [23]. This suggests the cohort obtained is broadly representative of the wider 
allopurinol treated primary care population. Unfortunately only 25.8% of these patients had 
the required BP readings but analysis found few differences between this group and all 
allopurinol exposed patients (data not shown). Adjustment was made for potential 
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confounding variables but a concealed confounder cannot be excluded. In order to further 
limit these factors we included a secondary analysis of a propensity matched sample which, 
while smaller, confirmed an independent fall in BP following allopurinol initiation. The 
baseline BP differed between groups and was higher in controls. This difference persisted 
after matching but was adjusted for in all analyses.  This could confound results, particularly 
as it may influence BP treatments, but we are reassured that results were consistent in the 
subgroup with no medication changes. The time between BP measurements is an important 
potential confounder and differed between groups but this was also adjusted for in the 
regression models. One further potential confounder is non-steroidal anti-inflammatory drug 
(NSAID) use. As would be expected, NSAID use was highly prevalent in the allopurinol 
group. NSAID use increases the BP [24] and this would likely bias the results towards the 
null and attenuate the fall in BP seen. Although we explored the relationship between 
baseline uric acid level and change in BP, the sample size was small and we could not assess 
change in uric acid level. The effect of allopurinol on BP in hyperuricaemic and 
normouricaemic patients warrants further study. We used clinic BP, which are highly 
variable rather than the gold standard ambulatory BP monitoring.  Further, although the 
CPRD is accurate in recording prescriptions issued, it is not possible to confirm patient 
adherence to therapy, although our results were consistent in patients taking no BP drugs. We 
also did not include a group of patients who withdrew BP medication, nor did we explore the 
effect of allopurinol initiation across different classes of BP lowering drugs and we were 
unable to study the effect of changes in BP medication doses. We have not explored use of 
other xanthine oxidase inhibitors such as Febuxostat. All of these areas warrant further study. 
 
Perspectives 
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Hypertension is a key risk factor for coronary heart disease and stroke and hyperuricaemia is 
known to have a role in the development of hypertension in adolescents. New treatments are 
needed to control BP and reduce associated risk. Allopurinol is an appealing drug for further 
study. It lowers BP in adolescents and a small (albeit limited meta-analysis) and our data 
suggests it may lower BP in older adults. Prospective randomised controlled and blinded 
studies of allopurinol use in adults with hypertension are needed to clarify whether it has a 
role in treatment of hypertension. Further studies are also needed to elucidate whether any 
effect of allopurinol in adults with hypertension are mediated via uric acid reduction or 
through its other effects. 
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Novelty and Significance 
 
What is New? 
Allopurinol initiation is associated with a fall in blood pressure in older adults with 
hypertension. 
What is Relevant? 
Allopurinol is an attractive drug for further study in patients with hypertension. 
Summary 
After adjustment for potential confounding factors, allopurinol initiation was associated with 
an independent fall in blood pressure.  
 
Figure Legends 
 
 
Figure 1: Flow chart of study participants. CPRD: Clinical Practice Research Datalink. 
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TABLES  
 
Table 1: Baseline Characteristics for patients in the allopurinol-exposed and control 
groups, before and after propensity matching. 
Variable Allopurin
ol 
Exposed 
Patients 
(365) 
Control 
Patients 
(6678) 
P- 
valu
e 
Propensity 
Matched 
Allopurinol 
Exposed 
Patients 
(313) 
Propensity 
Matched 
Control 
Patients 
(313) 
P- 
valu
e 
Age, years 
[mean(SD)] 
72.9 (5.3) 72.6 (5.82) 0.34
6  
72.6 (5.33) 72.4 (5.64) 0.60
5 
Female Sex* 192 
(52.6%) 
3511 
(52.6%) 
0.67
9 
161 (49.8%) 162 (51.8%) 0.93
6 
Smoking Status* 31 (8.2%) 760 (11.4%) 0.05
5 
26 (8.3%) 32 (10.2%) 0.43
0 
BMI (kg/m2) 
[mean(SD)] 
28.2 (4.1) 26.1 (4.04) 0.00
0 
28.22 (4.05) 28.51 (5.58) 0.46
2 
Diabetes* 127 
(34.8%) 
1453 
(21.8%) 
0.00
0 
112 (35.8%) 112 (35.8%) 1.00 
Ischaemic heart 
disease* 
106 (29%) 1214 
(18.2%) 
0.00
0 
91 (29.1%) 82 (26.3%) 0.42
1 
Peripheral  
vascular 
4 (1.1%) 91 (1.4%) 0.66
3 
4 (1.3%) 4 (1.3%) 1.00
0 
  
21 
disease* 
Cerebrovascular 
disease* 
25 (6.8%) 615 (9.2%) 0.12
3 
20 (6.4%) 21 (6.7%) 0.87
2 
SBP (mmHg) 
[mean(SD)] 
148.7 
(21.2) 
161.1 (21.9) 0.00
0 
148.3 (21.2) 161.8 (21.3) 0.00
0 
DBP (mmHg) 
[mean(SD)] 
79.8 (10.9) 87.5 (10.8) 0.00
0 
79.6 (11.07) 87.46 
(10.50) 
0.00
0 
Time between 
baseline BP and 
allopurinol 
exposure (days) 
[median (IQR)] 
52.0 (12-
123) 
- - 53.0 (10-
126) 
- - 
Allopurinol 
prescriptions 
[median (IQR)] 
13 (4-36) - - 7 (3-18) - - 
Time between 
BP reading 
(days) [median 
(IQR)] † 
454 (168 – 
1174) 
171 (84-
351.25) 
0.00
0 
410 (168 – 
1121) 
301 (117.5 – 
1032) 
0.04
9 
New 
antihypertensive
s* 
103 
(28.1%) 
660 (9.9%) 0.00
0 
90 (28.8%) 98 (31.3%) 0.48
5 
No or continued 
unchanged 
263 
(71.9%) 
6018 
(90.1%) 
0.00
0 
223 (71.2%) 215 (68.7%) 0.48
5 
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antihypertensive
s* 
 
* Denotes Chi-Squared test used for categorical variables. †Denotes Mann Whitney test 
used as data was non-parametric. All other continuous variables were analysed using 
Independent T-tests. 
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Table 2: The difference in the change of blood pressure between allopurinol exposed 
(365) and control patients (6678). 
Whole Cohort   
 SBP (mmHg) DBP (mmHg) 
 
 
Mean SD 95%CI p-
value 
Mean SD 95%CI p-value 
No / continued * 2.08 1.4 -0.59 to 4.75 0.127 1.72 0.8 0.38 to 3.07 0.032 
New antihypertensive 
treatment 
-4.81 2.8 -10.21 to 0.60 0.081 -2.56 1.4 -5.36 to 0.24 0.073 
Propensity Matched Sample 
No / continued * 3.02 2.2 -1.24 to 7.26 0.165 1.71 1.1 -0.51 to 3.93 0.130 
New antihypertensive 
treatment  
-2.20 4.0 -10.09 to 5.69 0.583 0.271 2.0 -3.40 to 4.57 0.771 
Differences are expressed as control – allopurinol-exposed, positive values show blood 
pressure to have fallen to a greater extent in allopurinol exposed patients. P-value based on 
independent sample T-test. * = no or continued antihypertensive treatment 
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Table 3: Regression analysis for the change in systolic and diastolic BP.  
A- Whole group data (365/6678) 
Variable Beta 95% CI for Beta P value 
  Lower limit Upper limit  
SBP change in ‘no or continued unchanged’ antihypertensive patients 
Allopurinol use  -7.42 -10.104 -4.744 0.000 
DBP change in ‘no or continued unchanged’ antihypertensive patients 
Allopurinol use  -5.39 -6.719 -4.050 0.000 
SBP change in new antihypertensive patients 
Allopurinol use -9.23 -14.880 -3.582 0.001 
DBP change in new antihypertensive patients 
Allopurinol use -6.71 -9.423 -3.994 0.000 
B- Propensity matched data (313/313) 
Variable Beta 95% CI for Beta P value 
  Lower limit Upper limit  
SBP change in ‘no or continued unchanged’ antihypertensive patients 
Allopurinol use  -6.83 -10.89 -2.761 0.001 
DBP change in ‘no or continued unchanged’ antihypertensive patients 
Allopurinol use  -4.45 -6.649 -2.258 0.000 
SBP change in new antihypertensive patients 
Allopurinol use -11.35 -19.61 -3.081 0.007 
DBP change in new antihypertensive patients 
Allopurinol use -8.11 -12.07 -4.147 0.000 
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Regression models included age, smoking, BMI, diabetes, ischaemic heart disease, peripheral 
vascular disease, cerebrovascular disease, baseline BP, days between BP measurements and 
allopurinol use.  
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
